NB202 / Neologics Biosci - LARVOL DELTA

NB202: A bispecific anti-PD1/TIM-3 antibody for cancer immunotherapy (AACR 2024) - "In classic MLR (mixed lymphocyte reaction) and T cell stimulation assays, NB202 has exhibited superior efficacy compared to the combination of anti-PD1 mAb and anti-TIM3 monoclonal antibodies as it significantly enhances the secretion level of interferon-gamma (IFN-gamma), and particularly interleukin-2 (IL-2). Moreover, in an anti-PD1 resistant mouse model, NB202 has shown promising efficacy results."

IO biomarker • Oncology • HAVCR2 • IFNG • IL2